nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—ABCB1—ovarian cancer	0.318	1	CbGaD
Paroxetine—ABCB1—Topotecan—ovarian cancer	0.0439	0.182	CbGbCtD
Paroxetine—CYP2C8—Paclitaxel—ovarian cancer	0.0321	0.133	CbGbCtD
Paroxetine—ABCB1—Vinorelbine—ovarian cancer	0.0309	0.128	CbGbCtD
Paroxetine—CYP2D6—Vinorelbine—ovarian cancer	0.0291	0.121	CbGbCtD
Paroxetine—CYP2B6—Doxorubicin—ovarian cancer	0.0228	0.0946	CbGbCtD
Paroxetine—CYP2C9—Paclitaxel—ovarian cancer	0.0224	0.0927	CbGbCtD
Paroxetine—ABCB1—Paclitaxel—ovarian cancer	0.0217	0.09	CbGbCtD
Paroxetine—ABCB1—Docetaxel—ovarian cancer	0.0157	0.0651	CbGbCtD
Paroxetine—ABCB1—Doxorubicin—ovarian cancer	0.0117	0.0485	CbGbCtD
Paroxetine—CYP2D6—Doxorubicin—ovarian cancer	0.011	0.0457	CbGbCtD
Paroxetine—CHRM3—muscle of abdomen—ovarian cancer	0.00866	0.203	CbGeAlD
Paroxetine—HTR2A—vein—ovarian cancer	0.00396	0.093	CbGeAlD
Paroxetine—TACR1—female reproductive system—ovarian cancer	0.00186	0.0437	CbGeAlD
Paroxetine—CHRM5—epithelium—ovarian cancer	0.00184	0.0433	CbGeAlD
Paroxetine—TACR1—testis—ovarian cancer	0.0015	0.0353	CbGeAlD
Paroxetine—CHRM4—testis—ovarian cancer	0.00141	0.0332	CbGeAlD
Paroxetine—TACR1—lymph node—ovarian cancer	0.00109	0.0256	CbGeAlD
Paroxetine—SLC6A2—decidua—ovarian cancer	0.000962	0.0226	CbGeAlD
Paroxetine—SLC6A4—female reproductive system—ovarian cancer	0.000859	0.0202	CbGeAlD
Paroxetine—CHRM1—female reproductive system—ovarian cancer	0.000856	0.0201	CbGeAlD
Paroxetine—SLC6A2—gonad—ovarian cancer	0.000847	0.0199	CbGeAlD
Paroxetine—CHRM3—female reproductive system—ovarian cancer	0.000766	0.018	CbGeAlD
Paroxetine—SLC6A3—testis—ovarian cancer	0.000757	0.0178	CbGeAlD
Paroxetine—SLC6A2—female reproductive system—ovarian cancer	0.000757	0.0178	CbGeAlD
Paroxetine—CYP2C8—endometrium—ovarian cancer	0.00075	0.0176	CbGeAlD
Paroxetine—HTR2A—embryo—ovarian cancer	0.00075	0.0176	CbGeAlD
Paroxetine—CHRM3—female gonad—ovarian cancer	0.000697	0.0164	CbGeAlD
Paroxetine—CYP2B6—gonad—ovarian cancer	0.000624	0.0146	CbGeAlD
Paroxetine—CYP2C8—female reproductive system—ovarian cancer	0.000622	0.0146	CbGeAlD
Paroxetine—CHRM3—testis—ovarian cancer	0.000618	0.0145	CbGeAlD
Paroxetine—HTR2A—epithelium—ovarian cancer	0.000612	0.0144	CbGeAlD
Paroxetine—SLC6A2—testis—ovarian cancer	0.000611	0.0143	CbGeAlD
Paroxetine—CYP2C8—vagina—ovarian cancer	0.000562	0.0132	CbGeAlD
Paroxetine—CYP2B6—female reproductive system—ovarian cancer	0.000558	0.0131	CbGeAlD
Paroxetine—CYP2C9—female reproductive system—ovarian cancer	0.000552	0.013	CbGeAlD
Paroxetine—ABCB1—myometrium—ovarian cancer	0.000511	0.012	CbGeAlD
Paroxetine—HTR2A—gonad—ovarian cancer	0.000509	0.0119	CbGeAlD
Paroxetine—CYP2B6—vagina—ovarian cancer	0.000504	0.0118	CbGeAlD
Paroxetine—CYP2C8—testis—ovarian cancer	0.000502	0.0118	CbGeAlD
Paroxetine—ABCB1—embryo—ovarian cancer	0.000492	0.0115	CbGeAlD
Paroxetine—HTR2A—female reproductive system—ovarian cancer	0.000455	0.0107	CbGeAlD
Paroxetine—CYP2B6—testis—ovarian cancer	0.00045	0.0106	CbGeAlD
Paroxetine—SLC6A2—lymph node—ovarian cancer	0.000443	0.0104	CbGeAlD
Paroxetine—CYP2D6—female reproductive system—ovarian cancer	0.000414	0.00972	CbGeAlD
Paroxetine—HTR2A—vagina—ovarian cancer	0.000411	0.00965	CbGeAlD
Paroxetine—ABCB1—epithelium—ovarian cancer	0.000401	0.00941	CbGeAlD
Paroxetine—ABCB1—uterine cervix—ovarian cancer	0.000398	0.00933	CbGeAlD
Paroxetine—ABCB1—decidua—ovarian cancer	0.000379	0.00889	CbGeAlD
Paroxetine—CYP2D6—female gonad—ovarian cancer	0.000377	0.00884	CbGeAlD
Paroxetine—HTR2A—testis—ovarian cancer	0.000367	0.00861	CbGeAlD
Paroxetine—ABCB1—endometrium—ovarian cancer	0.00036	0.00844	CbGeAlD
Paroxetine—CYP2D6—testis—ovarian cancer	0.000334	0.00784	CbGeAlD
Paroxetine—ABCB1—gonad—ovarian cancer	0.000334	0.00783	CbGeAlD
Paroxetine—ABCB1—uterus—ovarian cancer	0.000332	0.00778	CbGeAlD
Paroxetine—ABCB1—female reproductive system—ovarian cancer	0.000298	0.00699	CbGeAlD
Paroxetine—ABCB1—bone marrow—ovarian cancer	0.000281	0.0066	CbGeAlD
Paroxetine—ABCB1—female gonad—ovarian cancer	0.000271	0.00636	CbGeAlD
Paroxetine—ABCB1—vagina—ovarian cancer	0.00027	0.00632	CbGeAlD
Paroxetine—ABCB1—testis—ovarian cancer	0.000241	0.00564	CbGeAlD
Paroxetine—ABCB1—lymph node—ovarian cancer	0.000174	0.00409	CbGeAlD
Paroxetine—Pollakiuria—Doxorubicin—ovarian cancer	0.000114	0.000326	CcSEcCtD
Paroxetine—Constipation—Paclitaxel—ovarian cancer	0.000113	0.000325	CcSEcCtD
Paroxetine—Pain—Paclitaxel—ovarian cancer	0.000113	0.000325	CcSEcCtD
Paroxetine—Haematuria—Epirubicin—ovarian cancer	0.000113	0.000325	CcSEcCtD
Paroxetine—Confusional state—Docetaxel—ovarian cancer	0.000113	0.000325	CcSEcCtD
Paroxetine—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000112	0.000323	CcSEcCtD
Paroxetine—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000112	0.000322	CcSEcCtD
Paroxetine—Oedema—Docetaxel—ovarian cancer	0.000112	0.000322	CcSEcCtD
Paroxetine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000112	0.000322	CcSEcCtD
Paroxetine—Weight increased—Doxorubicin—ovarian cancer	0.000112	0.000322	CcSEcCtD
Paroxetine—Epistaxis—Epirubicin—ovarian cancer	0.000112	0.000321	CcSEcCtD
Paroxetine—Infection—Docetaxel—ovarian cancer	0.000112	0.00032	CcSEcCtD
Paroxetine—Weight decreased—Doxorubicin—ovarian cancer	0.000111	0.00032	CcSEcCtD
Paroxetine—Sinusitis—Epirubicin—ovarian cancer	0.000111	0.00032	CcSEcCtD
Paroxetine—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000111	0.000319	CcSEcCtD
Paroxetine—Agranulocytosis—Epirubicin—ovarian cancer	0.000111	0.000318	CcSEcCtD
Paroxetine—Pneumonia—Doxorubicin—ovarian cancer	0.00011	0.000317	CcSEcCtD
Paroxetine—Shock—Docetaxel—ovarian cancer	0.00011	0.000317	CcSEcCtD
Paroxetine—Nervous system disorder—Docetaxel—ovarian cancer	0.00011	0.000316	CcSEcCtD
Paroxetine—Thrombocytopenia—Docetaxel—ovarian cancer	0.00011	0.000315	CcSEcCtD
Paroxetine—Drowsiness—Doxorubicin—ovarian cancer	0.00011	0.000315	CcSEcCtD
Paroxetine—Tachycardia—Docetaxel—ovarian cancer	0.00011	0.000314	CcSEcCtD
Paroxetine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000109	0.000313	CcSEcCtD
Paroxetine—Skin disorder—Docetaxel—ovarian cancer	0.000109	0.000313	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000109	0.000312	CcSEcCtD
Paroxetine—Bradycardia—Epirubicin—ovarian cancer	0.000108	0.000311	CcSEcCtD
Paroxetine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000108	0.000311	CcSEcCtD
Paroxetine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000108	0.000309	CcSEcCtD
Paroxetine—Haemoglobin—Epirubicin—ovarian cancer	0.000107	0.000307	CcSEcCtD
Paroxetine—Stomatitis—Doxorubicin—ovarian cancer	0.000107	0.000307	CcSEcCtD
Paroxetine—Jaundice—Doxorubicin—ovarian cancer	0.000107	0.000307	CcSEcCtD
Paroxetine—Rhinitis—Epirubicin—ovarian cancer	0.000107	0.000306	CcSEcCtD
Paroxetine—Conjunctivitis—Doxorubicin—ovarian cancer	0.000107	0.000306	CcSEcCtD
Paroxetine—Urinary tract infection—Doxorubicin—ovarian cancer	0.000107	0.000306	CcSEcCtD
Paroxetine—Haemorrhage—Epirubicin—ovarian cancer	0.000107	0.000306	CcSEcCtD
Paroxetine—Hepatitis—Epirubicin—ovarian cancer	0.000107	0.000306	CcSEcCtD
Paroxetine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000106	0.000304	CcSEcCtD
Paroxetine—Pharyngitis—Epirubicin—ovarian cancer	0.000106	0.000303	CcSEcCtD
Paroxetine—Sweating—Doxorubicin—ovarian cancer	0.000105	0.000302	CcSEcCtD
Paroxetine—Urticaria—Paclitaxel—ovarian cancer	0.000105	0.000302	CcSEcCtD
Paroxetine—Oedema peripheral—Epirubicin—ovarian cancer	0.000105	0.000301	CcSEcCtD
Paroxetine—Hypotension—Docetaxel—ovarian cancer	0.000105	0.000301	CcSEcCtD
Paroxetine—Haematuria—Doxorubicin—ovarian cancer	0.000105	0.0003	CcSEcCtD
Paroxetine—Connective tissue disorder—Epirubicin—ovarian cancer	0.000105	0.0003	CcSEcCtD
Paroxetine—Abdominal pain—Paclitaxel—ovarian cancer	0.000105	0.0003	CcSEcCtD
Paroxetine—Body temperature increased—Paclitaxel—ovarian cancer	0.000105	0.0003	CcSEcCtD
Paroxetine—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000104	0.000298	CcSEcCtD
Paroxetine—Epistaxis—Doxorubicin—ovarian cancer	0.000104	0.000297	CcSEcCtD
Paroxetine—Sinusitis—Doxorubicin—ovarian cancer	0.000103	0.000296	CcSEcCtD
Paroxetine—Visual impairment—Epirubicin—ovarian cancer	0.000103	0.000295	CcSEcCtD
Paroxetine—Agranulocytosis—Doxorubicin—ovarian cancer	0.000103	0.000294	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000102	0.000293	CcSEcCtD
Paroxetine—Insomnia—Docetaxel—ovarian cancer	0.000102	0.000291	CcSEcCtD
Paroxetine—Paraesthesia—Docetaxel—ovarian cancer	0.000101	0.000289	CcSEcCtD
Paroxetine—Erythema multiforme—Epirubicin—ovarian cancer	0.000101	0.000289	CcSEcCtD
Paroxetine—Bradycardia—Doxorubicin—ovarian cancer	0.0001	0.000288	CcSEcCtD
Paroxetine—Dyspnoea—Docetaxel—ovarian cancer	0.0001	0.000287	CcSEcCtD
Paroxetine—Somnolence—Docetaxel—ovarian cancer	9.98e-05	0.000286	CcSEcCtD
Paroxetine—Eye disorder—Epirubicin—ovarian cancer	9.96e-05	0.000286	CcSEcCtD
Paroxetine—Tinnitus—Epirubicin—ovarian cancer	9.94e-05	0.000285	CcSEcCtD
Paroxetine—Haemoglobin—Doxorubicin—ovarian cancer	9.91e-05	0.000284	CcSEcCtD
Paroxetine—Flushing—Epirubicin—ovarian cancer	9.89e-05	0.000284	CcSEcCtD
Paroxetine—Cardiac disorder—Epirubicin—ovarian cancer	9.89e-05	0.000284	CcSEcCtD
Paroxetine—Rhinitis—Doxorubicin—ovarian cancer	9.89e-05	0.000284	CcSEcCtD
Paroxetine—Dyspepsia—Docetaxel—ovarian cancer	9.88e-05	0.000283	CcSEcCtD
Paroxetine—Haemorrhage—Doxorubicin—ovarian cancer	9.86e-05	0.000283	CcSEcCtD
Paroxetine—Hepatitis—Doxorubicin—ovarian cancer	9.86e-05	0.000283	CcSEcCtD
Paroxetine—Hypoaesthesia—Doxorubicin—ovarian cancer	9.81e-05	0.000281	CcSEcCtD
Paroxetine—Pharyngitis—Doxorubicin—ovarian cancer	9.79e-05	0.000281	CcSEcCtD
Paroxetine—Decreased appetite—Docetaxel—ovarian cancer	9.76e-05	0.00028	CcSEcCtD
Paroxetine—Hypersensitivity—Paclitaxel—ovarian cancer	9.76e-05	0.00028	CcSEcCtD
Paroxetine—Oedema peripheral—Doxorubicin—ovarian cancer	9.71e-05	0.000279	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Docetaxel—ovarian cancer	9.69e-05	0.000278	CcSEcCtD
Paroxetine—Connective tissue disorder—Doxorubicin—ovarian cancer	9.69e-05	0.000278	CcSEcCtD
Paroxetine—Fatigue—Docetaxel—ovarian cancer	9.68e-05	0.000278	CcSEcCtD
Paroxetine—Angiopathy—Epirubicin—ovarian cancer	9.67e-05	0.000277	CcSEcCtD
Paroxetine—Immune system disorder—Epirubicin—ovarian cancer	9.63e-05	0.000276	CcSEcCtD
Paroxetine—Mediastinal disorder—Epirubicin—ovarian cancer	9.61e-05	0.000276	CcSEcCtD
Paroxetine—Pain—Docetaxel—ovarian cancer	9.6e-05	0.000275	CcSEcCtD
Paroxetine—Constipation—Docetaxel—ovarian cancer	9.6e-05	0.000275	CcSEcCtD
Paroxetine—Chills—Epirubicin—ovarian cancer	9.56e-05	0.000274	CcSEcCtD
Paroxetine—Arrhythmia—Epirubicin—ovarian cancer	9.52e-05	0.000273	CcSEcCtD
Paroxetine—Visual impairment—Doxorubicin—ovarian cancer	9.5e-05	0.000273	CcSEcCtD
Paroxetine—Asthenia—Paclitaxel—ovarian cancer	9.5e-05	0.000273	CcSEcCtD
Paroxetine—Alopecia—Epirubicin—ovarian cancer	9.42e-05	0.00027	CcSEcCtD
Paroxetine—Pruritus—Paclitaxel—ovarian cancer	9.37e-05	0.000269	CcSEcCtD
Paroxetine—Mental disorder—Epirubicin—ovarian cancer	9.34e-05	0.000268	CcSEcCtD
Paroxetine—Erythema multiforme—Doxorubicin—ovarian cancer	9.32e-05	0.000267	CcSEcCtD
Paroxetine—Erythema—Epirubicin—ovarian cancer	9.28e-05	0.000266	CcSEcCtD
Paroxetine—Malnutrition—Epirubicin—ovarian cancer	9.28e-05	0.000266	CcSEcCtD
Paroxetine—Feeling abnormal—Docetaxel—ovarian cancer	9.25e-05	0.000265	CcSEcCtD
Paroxetine—Eye disorder—Doxorubicin—ovarian cancer	9.22e-05	0.000264	CcSEcCtD
Paroxetine—Tinnitus—Doxorubicin—ovarian cancer	9.19e-05	0.000264	CcSEcCtD
Paroxetine—Gastrointestinal pain—Docetaxel—ovarian cancer	9.18e-05	0.000263	CcSEcCtD
Paroxetine—Flushing—Doxorubicin—ovarian cancer	9.15e-05	0.000263	CcSEcCtD
Paroxetine—Cardiac disorder—Doxorubicin—ovarian cancer	9.15e-05	0.000263	CcSEcCtD
Paroxetine—Flatulence—Epirubicin—ovarian cancer	9.14e-05	0.000262	CcSEcCtD
Paroxetine—Tension—Epirubicin—ovarian cancer	9.1e-05	0.000261	CcSEcCtD
Paroxetine—Dysgeusia—Epirubicin—ovarian cancer	9.09e-05	0.000261	CcSEcCtD
Paroxetine—Diarrhoea—Paclitaxel—ovarian cancer	9.06e-05	0.00026	CcSEcCtD
Paroxetine—Nervousness—Epirubicin—ovarian cancer	9.01e-05	0.000258	CcSEcCtD
Paroxetine—Back pain—Epirubicin—ovarian cancer	8.97e-05	0.000257	CcSEcCtD
Paroxetine—Angiopathy—Doxorubicin—ovarian cancer	8.95e-05	0.000257	CcSEcCtD
Paroxetine—Muscle spasms—Epirubicin—ovarian cancer	8.92e-05	0.000256	CcSEcCtD
Paroxetine—Immune system disorder—Doxorubicin—ovarian cancer	8.91e-05	0.000256	CcSEcCtD
Paroxetine—Mediastinal disorder—Doxorubicin—ovarian cancer	8.89e-05	0.000255	CcSEcCtD
Paroxetine—Body temperature increased—Docetaxel—ovarian cancer	8.87e-05	0.000255	CcSEcCtD
Paroxetine—Abdominal pain—Docetaxel—ovarian cancer	8.87e-05	0.000255	CcSEcCtD
Paroxetine—Chills—Doxorubicin—ovarian cancer	8.85e-05	0.000254	CcSEcCtD
Paroxetine—Arrhythmia—Doxorubicin—ovarian cancer	8.81e-05	0.000253	CcSEcCtD
Paroxetine—Dizziness—Paclitaxel—ovarian cancer	8.76e-05	0.000251	CcSEcCtD
Paroxetine—Vision blurred—Epirubicin—ovarian cancer	8.74e-05	0.000251	CcSEcCtD
Paroxetine—Alopecia—Doxorubicin—ovarian cancer	8.71e-05	0.00025	CcSEcCtD
Paroxetine—Mental disorder—Doxorubicin—ovarian cancer	8.64e-05	0.000248	CcSEcCtD
Paroxetine—Ill-defined disorder—Epirubicin—ovarian cancer	8.61e-05	0.000247	CcSEcCtD
Paroxetine—Erythema—Doxorubicin—ovarian cancer	8.58e-05	0.000246	CcSEcCtD
Paroxetine—Malnutrition—Doxorubicin—ovarian cancer	8.58e-05	0.000246	CcSEcCtD
Paroxetine—Anaemia—Epirubicin—ovarian cancer	8.57e-05	0.000246	CcSEcCtD
Paroxetine—Agitation—Epirubicin—ovarian cancer	8.53e-05	0.000245	CcSEcCtD
Paroxetine—Flatulence—Doxorubicin—ovarian cancer	8.46e-05	0.000243	CcSEcCtD
Paroxetine—Tension—Doxorubicin—ovarian cancer	8.42e-05	0.000242	CcSEcCtD
Paroxetine—Vomiting—Paclitaxel—ovarian cancer	8.42e-05	0.000242	CcSEcCtD
Paroxetine—Dysgeusia—Doxorubicin—ovarian cancer	8.41e-05	0.000241	CcSEcCtD
Paroxetine—Malaise—Epirubicin—ovarian cancer	8.37e-05	0.00024	CcSEcCtD
Paroxetine—Rash—Paclitaxel—ovarian cancer	8.35e-05	0.00024	CcSEcCtD
Paroxetine—Dermatitis—Paclitaxel—ovarian cancer	8.34e-05	0.000239	CcSEcCtD
Paroxetine—Nervousness—Doxorubicin—ovarian cancer	8.34e-05	0.000239	CcSEcCtD
Paroxetine—Vertigo—Epirubicin—ovarian cancer	8.34e-05	0.000239	CcSEcCtD
Paroxetine—Syncope—Epirubicin—ovarian cancer	8.32e-05	0.000239	CcSEcCtD
Paroxetine—Leukopenia—Epirubicin—ovarian cancer	8.3e-05	0.000238	CcSEcCtD
Paroxetine—Back pain—Doxorubicin—ovarian cancer	8.3e-05	0.000238	CcSEcCtD
Paroxetine—Headache—Paclitaxel—ovarian cancer	8.3e-05	0.000238	CcSEcCtD
Paroxetine—Hypersensitivity—Docetaxel—ovarian cancer	8.27e-05	0.000237	CcSEcCtD
Paroxetine—Muscle spasms—Doxorubicin—ovarian cancer	8.25e-05	0.000237	CcSEcCtD
Paroxetine—Palpitations—Epirubicin—ovarian cancer	8.2e-05	0.000235	CcSEcCtD
Paroxetine—Loss of consciousness—Epirubicin—ovarian cancer	8.15e-05	0.000234	CcSEcCtD
Paroxetine—Cough—Epirubicin—ovarian cancer	8.1e-05	0.000232	CcSEcCtD
Paroxetine—Vision blurred—Doxorubicin—ovarian cancer	8.09e-05	0.000232	CcSEcCtD
Paroxetine—Asthenia—Docetaxel—ovarian cancer	8.05e-05	0.000231	CcSEcCtD
Paroxetine—Convulsion—Epirubicin—ovarian cancer	8.04e-05	0.000231	CcSEcCtD
Paroxetine—Hypertension—Epirubicin—ovarian cancer	8.01e-05	0.00023	CcSEcCtD
Paroxetine—Ill-defined disorder—Doxorubicin—ovarian cancer	7.96e-05	0.000228	CcSEcCtD
Paroxetine—Pruritus—Docetaxel—ovarian cancer	7.94e-05	0.000228	CcSEcCtD
Paroxetine—Anaemia—Doxorubicin—ovarian cancer	7.93e-05	0.000228	CcSEcCtD
Paroxetine—Myalgia—Epirubicin—ovarian cancer	7.9e-05	0.000227	CcSEcCtD
Paroxetine—Chest pain—Epirubicin—ovarian cancer	7.9e-05	0.000227	CcSEcCtD
Paroxetine—Arthralgia—Epirubicin—ovarian cancer	7.9e-05	0.000227	CcSEcCtD
Paroxetine—Agitation—Doxorubicin—ovarian cancer	7.89e-05	0.000226	CcSEcCtD
Paroxetine—Anxiety—Epirubicin—ovarian cancer	7.87e-05	0.000226	CcSEcCtD
Paroxetine—Nausea—Paclitaxel—ovarian cancer	7.87e-05	0.000226	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	7.84e-05	0.000225	CcSEcCtD
Paroxetine—Discomfort—Epirubicin—ovarian cancer	7.8e-05	0.000224	CcSEcCtD
Paroxetine—Malaise—Doxorubicin—ovarian cancer	7.74e-05	0.000222	CcSEcCtD
Paroxetine—Dry mouth—Epirubicin—ovarian cancer	7.72e-05	0.000222	CcSEcCtD
Paroxetine—Vertigo—Doxorubicin—ovarian cancer	7.71e-05	0.000221	CcSEcCtD
Paroxetine—Syncope—Doxorubicin—ovarian cancer	7.7e-05	0.000221	CcSEcCtD
Paroxetine—Leukopenia—Doxorubicin—ovarian cancer	7.68e-05	0.00022	CcSEcCtD
Paroxetine—Diarrhoea—Docetaxel—ovarian cancer	7.68e-05	0.00022	CcSEcCtD
Paroxetine—Confusional state—Epirubicin—ovarian cancer	7.63e-05	0.000219	CcSEcCtD
Paroxetine—Palpitations—Doxorubicin—ovarian cancer	7.59e-05	0.000218	CcSEcCtD
Paroxetine—Anaphylactic shock—Epirubicin—ovarian cancer	7.57e-05	0.000217	CcSEcCtD
Paroxetine—Oedema—Epirubicin—ovarian cancer	7.57e-05	0.000217	CcSEcCtD
Paroxetine—Loss of consciousness—Doxorubicin—ovarian cancer	7.54e-05	0.000216	CcSEcCtD
Paroxetine—Infection—Epirubicin—ovarian cancer	7.52e-05	0.000216	CcSEcCtD
Paroxetine—Cough—Doxorubicin—ovarian cancer	7.49e-05	0.000215	CcSEcCtD
Paroxetine—Shock—Epirubicin—ovarian cancer	7.45e-05	0.000214	CcSEcCtD
Paroxetine—Convulsion—Doxorubicin—ovarian cancer	7.44e-05	0.000213	CcSEcCtD
Paroxetine—Nervous system disorder—Epirubicin—ovarian cancer	7.43e-05	0.000213	CcSEcCtD
Paroxetine—Dizziness—Docetaxel—ovarian cancer	7.42e-05	0.000213	CcSEcCtD
Paroxetine—Thrombocytopenia—Epirubicin—ovarian cancer	7.41e-05	0.000213	CcSEcCtD
Paroxetine—Hypertension—Doxorubicin—ovarian cancer	7.41e-05	0.000213	CcSEcCtD
Paroxetine—Tachycardia—Epirubicin—ovarian cancer	7.39e-05	0.000212	CcSEcCtD
Paroxetine—Skin disorder—Epirubicin—ovarian cancer	7.35e-05	0.000211	CcSEcCtD
Paroxetine—Hyperhidrosis—Epirubicin—ovarian cancer	7.32e-05	0.00021	CcSEcCtD
Paroxetine—Arthralgia—Doxorubicin—ovarian cancer	7.31e-05	0.00021	CcSEcCtD
Paroxetine—Chest pain—Doxorubicin—ovarian cancer	7.31e-05	0.00021	CcSEcCtD
Paroxetine—Myalgia—Doxorubicin—ovarian cancer	7.31e-05	0.00021	CcSEcCtD
Paroxetine—Anxiety—Doxorubicin—ovarian cancer	7.28e-05	0.000209	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	7.26e-05	0.000208	CcSEcCtD
Paroxetine—Discomfort—Doxorubicin—ovarian cancer	7.22e-05	0.000207	CcSEcCtD
Paroxetine—Dry mouth—Doxorubicin—ovarian cancer	7.15e-05	0.000205	CcSEcCtD
Paroxetine—Vomiting—Docetaxel—ovarian cancer	7.14e-05	0.000205	CcSEcCtD
Paroxetine—Rash—Docetaxel—ovarian cancer	7.08e-05	0.000203	CcSEcCtD
Paroxetine—Hypotension—Epirubicin—ovarian cancer	7.08e-05	0.000203	CcSEcCtD
Paroxetine—Dermatitis—Docetaxel—ovarian cancer	7.07e-05	0.000203	CcSEcCtD
Paroxetine—Confusional state—Doxorubicin—ovarian cancer	7.06e-05	0.000203	CcSEcCtD
Paroxetine—Headache—Docetaxel—ovarian cancer	7.03e-05	0.000202	CcSEcCtD
Paroxetine—Anaphylactic shock—Doxorubicin—ovarian cancer	7.01e-05	0.000201	CcSEcCtD
Paroxetine—Oedema—Doxorubicin—ovarian cancer	7.01e-05	0.000201	CcSEcCtD
Paroxetine—Infection—Doxorubicin—ovarian cancer	6.96e-05	0.0002	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	6.9e-05	0.000198	CcSEcCtD
Paroxetine—Shock—Doxorubicin—ovarian cancer	6.89e-05	0.000198	CcSEcCtD
Paroxetine—Nervous system disorder—Doxorubicin—ovarian cancer	6.87e-05	0.000197	CcSEcCtD
Paroxetine—Thrombocytopenia—Doxorubicin—ovarian cancer	6.86e-05	0.000197	CcSEcCtD
Paroxetine—Insomnia—Epirubicin—ovarian cancer	6.85e-05	0.000196	CcSEcCtD
Paroxetine—Tachycardia—Doxorubicin—ovarian cancer	6.84e-05	0.000196	CcSEcCtD
Paroxetine—Skin disorder—Doxorubicin—ovarian cancer	6.81e-05	0.000195	CcSEcCtD
Paroxetine—Paraesthesia—Epirubicin—ovarian cancer	6.8e-05	0.000195	CcSEcCtD
Paroxetine—Hyperhidrosis—Doxorubicin—ovarian cancer	6.77e-05	0.000194	CcSEcCtD
Paroxetine—Dyspnoea—Epirubicin—ovarian cancer	6.75e-05	0.000194	CcSEcCtD
Paroxetine—Somnolence—Epirubicin—ovarian cancer	6.73e-05	0.000193	CcSEcCtD
Paroxetine—Nausea—Docetaxel—ovarian cancer	6.67e-05	0.000191	CcSEcCtD
Paroxetine—Dyspepsia—Epirubicin—ovarian cancer	6.67e-05	0.000191	CcSEcCtD
Paroxetine—Decreased appetite—Epirubicin—ovarian cancer	6.58e-05	0.000189	CcSEcCtD
Paroxetine—Hypotension—Doxorubicin—ovarian cancer	6.55e-05	0.000188	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Epirubicin—ovarian cancer	6.54e-05	0.000188	CcSEcCtD
Paroxetine—Fatigue—Epirubicin—ovarian cancer	6.53e-05	0.000187	CcSEcCtD
Paroxetine—Pain—Epirubicin—ovarian cancer	6.47e-05	0.000186	CcSEcCtD
Paroxetine—Constipation—Epirubicin—ovarian cancer	6.47e-05	0.000186	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	6.38e-05	0.000183	CcSEcCtD
Paroxetine—Insomnia—Doxorubicin—ovarian cancer	6.34e-05	0.000182	CcSEcCtD
Paroxetine—Paraesthesia—Doxorubicin—ovarian cancer	6.29e-05	0.00018	CcSEcCtD
Paroxetine—Dyspnoea—Doxorubicin—ovarian cancer	6.25e-05	0.000179	CcSEcCtD
Paroxetine—Feeling abnormal—Epirubicin—ovarian cancer	6.24e-05	0.000179	CcSEcCtD
Paroxetine—Somnolence—Doxorubicin—ovarian cancer	6.23e-05	0.000179	CcSEcCtD
Paroxetine—Gastrointestinal pain—Epirubicin—ovarian cancer	6.19e-05	0.000178	CcSEcCtD
Paroxetine—Dyspepsia—Doxorubicin—ovarian cancer	6.17e-05	0.000177	CcSEcCtD
Paroxetine—Decreased appetite—Doxorubicin—ovarian cancer	6.09e-05	0.000175	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	6.05e-05	0.000174	CcSEcCtD
Paroxetine—Fatigue—Doxorubicin—ovarian cancer	6.04e-05	0.000173	CcSEcCtD
Paroxetine—Urticaria—Epirubicin—ovarian cancer	6.02e-05	0.000173	CcSEcCtD
Paroxetine—Constipation—Doxorubicin—ovarian cancer	5.99e-05	0.000172	CcSEcCtD
Paroxetine—Pain—Doxorubicin—ovarian cancer	5.99e-05	0.000172	CcSEcCtD
Paroxetine—Abdominal pain—Epirubicin—ovarian cancer	5.99e-05	0.000172	CcSEcCtD
Paroxetine—Body temperature increased—Epirubicin—ovarian cancer	5.99e-05	0.000172	CcSEcCtD
Paroxetine—Feeling abnormal—Doxorubicin—ovarian cancer	5.77e-05	0.000166	CcSEcCtD
Paroxetine—Gastrointestinal pain—Doxorubicin—ovarian cancer	5.73e-05	0.000164	CcSEcCtD
Paroxetine—Hypersensitivity—Epirubicin—ovarian cancer	5.58e-05	0.00016	CcSEcCtD
Paroxetine—Urticaria—Doxorubicin—ovarian cancer	5.57e-05	0.00016	CcSEcCtD
Paroxetine—Abdominal pain—Doxorubicin—ovarian cancer	5.54e-05	0.000159	CcSEcCtD
Paroxetine—Body temperature increased—Doxorubicin—ovarian cancer	5.54e-05	0.000159	CcSEcCtD
Paroxetine—Asthenia—Epirubicin—ovarian cancer	5.43e-05	0.000156	CcSEcCtD
Paroxetine—Pruritus—Epirubicin—ovarian cancer	5.36e-05	0.000154	CcSEcCtD
Paroxetine—Diarrhoea—Epirubicin—ovarian cancer	5.18e-05	0.000149	CcSEcCtD
Paroxetine—Hypersensitivity—Doxorubicin—ovarian cancer	5.16e-05	0.000148	CcSEcCtD
Paroxetine—Asthenia—Doxorubicin—ovarian cancer	5.03e-05	0.000144	CcSEcCtD
Paroxetine—Dizziness—Epirubicin—ovarian cancer	5.01e-05	0.000144	CcSEcCtD
Paroxetine—Pruritus—Doxorubicin—ovarian cancer	4.96e-05	0.000142	CcSEcCtD
Paroxetine—Vomiting—Epirubicin—ovarian cancer	4.81e-05	0.000138	CcSEcCtD
Paroxetine—Diarrhoea—Doxorubicin—ovarian cancer	4.79e-05	0.000138	CcSEcCtD
Paroxetine—Rash—Epirubicin—ovarian cancer	4.77e-05	0.000137	CcSEcCtD
Paroxetine—Dermatitis—Epirubicin—ovarian cancer	4.77e-05	0.000137	CcSEcCtD
Paroxetine—Headache—Epirubicin—ovarian cancer	4.74e-05	0.000136	CcSEcCtD
Paroxetine—Dizziness—Doxorubicin—ovarian cancer	4.63e-05	0.000133	CcSEcCtD
Paroxetine—Nausea—Epirubicin—ovarian cancer	4.5e-05	0.000129	CcSEcCtD
Paroxetine—Vomiting—Doxorubicin—ovarian cancer	4.45e-05	0.000128	CcSEcCtD
Paroxetine—Rash—Doxorubicin—ovarian cancer	4.42e-05	0.000127	CcSEcCtD
Paroxetine—Dermatitis—Doxorubicin—ovarian cancer	4.41e-05	0.000127	CcSEcCtD
Paroxetine—Headache—Doxorubicin—ovarian cancer	4.39e-05	0.000126	CcSEcCtD
Paroxetine—Nausea—Doxorubicin—ovarian cancer	4.16e-05	0.000119	CcSEcCtD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.74e-06	0.000158	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CD—ovarian cancer	7.72e-06	0.000157	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6ST—ovarian cancer	7.71e-06	0.000157	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CXCL8—ovarian cancer	7.7e-06	0.000157	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CASP3—ovarian cancer	7.7e-06	0.000157	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ESR1—ovarian cancer	7.69e-06	0.000157	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL2—ovarian cancer	7.69e-06	0.000157	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6ST—ovarian cancer	7.67e-06	0.000156	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HRAS—ovarian cancer	7.65e-06	0.000156	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6—ovarian cancer	7.65e-06	0.000156	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6ST—ovarian cancer	7.64e-06	0.000156	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TYMS—ovarian cancer	7.59e-06	0.000155	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6ST—ovarian cancer	7.57e-06	0.000154	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CG—ovarian cancer	7.56e-06	0.000154	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CDKN1B—ovarian cancer	7.52e-06	0.000153	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCND1—ovarian cancer	7.5e-06	0.000153	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AKT1—ovarian cancer	7.44e-06	0.000152	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CTNNB1—ovarian cancer	7.42e-06	0.000151	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APC—ovarian cancer	7.41e-06	0.000151	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CG—ovarian cancer	7.41e-06	0.000151	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—NRAS—ovarian cancer	7.41e-06	0.000151	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CASP3—ovarian cancer	7.37e-06	0.00015	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APC—ovarian cancer	7.37e-06	0.00015	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CG—ovarian cancer	7.37e-06	0.00015	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—NRAS—ovarian cancer	7.37e-06	0.00015	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL2—ovarian cancer	7.36e-06	0.00015	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CG—ovarian cancer	7.34e-06	0.00015	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APC—ovarian cancer	7.34e-06	0.00015	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—NRAS—ovarian cancer	7.34e-06	0.00015	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6—ovarian cancer	7.33e-06	0.000149	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ABCB1—ovarian cancer	7.29e-06	0.000149	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—ovarian cancer	7.28e-06	0.000148	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APC—ovarian cancer	7.27e-06	0.000148	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CG—ovarian cancer	7.27e-06	0.000148	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—NRAS—ovarian cancer	7.27e-06	0.000148	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PTEN—ovarian cancer	7.23e-06	0.000148	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ABCB1—ovarian cancer	7.22e-06	0.000147	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCND1—ovarian cancer	7.18e-06	0.000146	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TYMS—ovarian cancer	7.15e-06	0.000146	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CTNNB1—ovarian cancer	7.11e-06	0.000145	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—MAPK3—ovarian cancer	7.09e-06	0.000145	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TYMS—ovarian cancer	7.09e-06	0.000145	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—ovarian cancer	7.06e-06	0.000144	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—MAPK3—ovarian cancer	7.06e-06	0.000144	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—MAPK3—ovarian cancer	7.03e-06	0.000143	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CAV1—ovarian cancer	7.02e-06	0.000143	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—ovarian cancer	6.97e-06	0.000142	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—MAPK3—ovarian cancer	6.97e-06	0.000142	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTEN—ovarian cancer	6.93e-06	0.000141	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—ovarian cancer	6.76e-06	0.000138	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—MAPK1—ovarian cancer	6.75e-06	0.000138	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EGFR—ovarian cancer	6.75e-06	0.000138	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CB—ovarian cancer	6.73e-06	0.000137	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—MAPK1—ovarian cancer	6.71e-06	0.000137	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EGFR—ovarian cancer	6.71e-06	0.000137	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.71e-06	0.000137	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—MAPK1—ovarian cancer	6.69e-06	0.000136	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EGFR—ovarian cancer	6.69e-06	0.000136	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CD—ovarian cancer	6.64e-06	0.000135	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—MAPK1—ovarian cancer	6.63e-06	0.000135	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EGFR—ovarian cancer	6.63e-06	0.000135	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—ovarian cancer	6.53e-06	0.000133	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CD—ovarian cancer	6.51e-06	0.000133	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CD—ovarian cancer	6.48e-06	0.000132	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—STAT3—ovarian cancer	6.47e-06	0.000132	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CD—ovarian cancer	6.46e-06	0.000132	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NRAS—ovarian cancer	6.45e-06	0.000132	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—PIK3CA—ovarian cancer	6.45e-06	0.000132	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—PIK3CA—ovarian cancer	6.42e-06	0.000131	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CG—ovarian cancer	6.4e-06	0.00013	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—PIK3CA—ovarian cancer	6.39e-06	0.00013	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CD—ovarian cancer	6.39e-06	0.00013	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—KRAS—ovarian cancer	6.38e-06	0.00013	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—KRAS—ovarian cancer	6.34e-06	0.000129	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—PIK3CA—ovarian cancer	6.33e-06	0.000129	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—KRAS—ovarian cancer	6.32e-06	0.000129	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—KRAS—ovarian cancer	6.26e-06	0.000128	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—ovarian cancer	6.26e-06	0.000128	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—STAT3—ovarian cancer	6.2e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK3—ovarian cancer	6.18e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NRAS—ovarian cancer	6.18e-06	0.000126	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CAV1—ovarian cancer	6.12e-06	0.000125	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MYC—ovarian cancer	6.01e-06	0.000123	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK3—ovarian cancer	5.92e-06	0.000121	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK1—ovarian cancer	5.88e-06	0.00012	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EGFR—ovarian cancer	5.88e-06	0.00012	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PIK3CA—ovarian cancer	5.86e-06	0.000119	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PIK3CA—ovarian cancer	5.83e-06	0.000119	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTEN—ovarian cancer	5.82e-06	0.000119	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PIK3CA—ovarian cancer	5.81e-06	0.000118	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CB—ovarian cancer	5.79e-06	0.000118	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CAV1—ovarian cancer	5.77e-06	0.000118	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MYC—ovarian cancer	5.76e-06	0.000117	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ERBB2—ovarian cancer	5.75e-06	0.000117	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PIK3CA—ovarian cancer	5.75e-06	0.000117	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ERBB2—ovarian cancer	5.72e-06	0.000117	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CAV1—ovarian cancer	5.72e-06	0.000117	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ERBB2—ovarian cancer	5.7e-06	0.000116	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MTOR—ovarian cancer	5.68e-06	0.000116	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CB—ovarian cancer	5.68e-06	0.000116	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ERBB2—ovarian cancer	5.65e-06	0.000115	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MTOR—ovarian cancer	5.65e-06	0.000115	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CB—ovarian cancer	5.65e-06	0.000115	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK1—ovarian cancer	5.63e-06	0.000115	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EGFR—ovarian cancer	5.63e-06	0.000115	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MTOR—ovarian cancer	5.63e-06	0.000115	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CB—ovarian cancer	5.63e-06	0.000115	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CD—ovarian cancer	5.62e-06	0.000115	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CG—ovarian cancer	5.57e-06	0.000114	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MTOR—ovarian cancer	5.57e-06	0.000114	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CB—ovarian cancer	5.57e-06	0.000114	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KRAS—ovarian cancer	5.56e-06	0.000113	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.46e-06	0.000111	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	5.45e-06	0.000111	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCL8—ovarian cancer	5.43e-06	0.000111	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	5.42e-06	0.000111	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCL8—ovarian cancer	5.41e-06	0.00011	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRAS—ovarian cancer	5.39e-06	0.00011	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRAS—ovarian cancer	5.37e-06	0.00011	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCL8—ovarian cancer	5.36e-06	0.000109	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	5.33e-06	0.000109	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRAS—ovarian cancer	5.32e-06	0.000109	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KRAS—ovarian cancer	5.32e-06	0.000109	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN1B—ovarian cancer	5.3e-06	0.000108	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN1B—ovarian cancer	5.28e-06	0.000108	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	5.27e-06	0.000107	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	5.25e-06	0.000107	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—ovarian cancer	5.24e-06	0.000107	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN1B—ovarian cancer	5.23e-06	0.000107	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—ovarian cancer	5.22e-06	0.000107	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP3—ovarian cancer	5.22e-06	0.000106	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL2—ovarian cancer	5.21e-06	0.000106	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CG—ovarian cancer	5.21e-06	0.000106	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP3—ovarian cancer	5.19e-06	0.000106	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—ovarian cancer	5.19e-06	0.000106	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL2—ovarian cancer	5.18e-06	0.000106	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP3—ovarian cancer	5.18e-06	0.000106	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—ovarian cancer	5.17e-06	0.000106	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL2—ovarian cancer	5.17e-06	0.000105	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—ovarian cancer	5.16e-06	0.000105	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—ovarian cancer	5.14e-06	0.000105	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP3—ovarian cancer	5.13e-06	0.000105	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL2—ovarian cancer	5.12e-06	0.000104	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PIK3CA—ovarian cancer	5.1e-06	0.000104	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—ovarian cancer	5.09e-06	0.000104	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCND1—ovarian cancer	5.08e-06	0.000104	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCND1—ovarian cancer	5.05e-06	0.000103	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCND1—ovarian cancer	5.04e-06	0.000103	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	5.03e-06	0.000103	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CTNNB1—ovarian cancer	5.01e-06	0.000102	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTEN—ovarian cancer	5e-06	0.000102	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCND1—ovarian cancer	4.99e-06	0.000102	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CTNNB1—ovarian cancer	4.99e-06	0.000102	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CTNNB1—ovarian cancer	4.94e-06	0.000101	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—ovarian cancer	4.94e-06	0.000101	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—ovarian cancer	4.93e-06	0.000101	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—ovarian cancer	4.91e-06	0.0001	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTEN—ovarian cancer	4.9e-06	0.0001	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CB—ovarian cancer	4.9e-06	0.0001	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CD—ovarian cancer	4.9e-06	9.99e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—ovarian cancer	4.89e-06	9.98e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PIK3CA—ovarian cancer	4.89e-06	9.97e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTEN—ovarian cancer	4.88e-06	9.95e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTEN—ovarian cancer	4.86e-06	9.92e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—ovarian cancer	4.84e-06	9.88e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTEN—ovarian cancer	4.82e-06	9.82e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	4.78e-06	9.76e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—ovarian cancer	4.76e-06	9.71e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—ovarian cancer	4.74e-06	9.68e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—ovarian cancer	4.73e-06	9.64e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRAS—ovarian cancer	4.72e-06	9.63e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—ovarian cancer	4.7e-06	9.58e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	4.62e-06	9.42e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CD—ovarian cancer	4.58e-06	9.33e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRAS—ovarian cancer	4.52e-06	9.22e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—ovarian cancer	4.52e-06	9.22e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	4.43e-06	9.03e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—ovarian cancer	4.41e-06	8.99e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—ovarian cancer	4.39e-06	8.96e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STAT3—ovarian cancer	4.39e-06	8.95e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NRAS—ovarian cancer	4.38e-06	8.92e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STAT3—ovarian cancer	4.36e-06	8.9e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NRAS—ovarian cancer	4.35e-06	8.88e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—ovarian cancer	4.35e-06	8.87e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STAT3—ovarian cancer	4.35e-06	8.87e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NRAS—ovarian cancer	4.34e-06	8.85e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—ovarian cancer	4.33e-06	8.83e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STAT3—ovarian cancer	4.31e-06	8.78e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NRAS—ovarian cancer	4.3e-06	8.76e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CB—ovarian cancer	4.27e-06	8.71e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTEN—ovarian cancer	4.24e-06	8.64e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	4.19e-06	8.55e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—ovarian cancer	4.17e-06	8.5e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK3—ovarian cancer	4.17e-06	8.5e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK3—ovarian cancer	4.15e-06	8.47e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK3—ovarian cancer	4.11e-06	8.39e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CA—ovarian cancer	4.1e-06	8.37e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MYC—ovarian cancer	4.08e-06	8.31e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MYC—ovarian cancer	4.05e-06	8.27e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MYC—ovarian cancer	4.04e-06	8.24e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4.02e-06	8.21e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MYC—ovarian cancer	4e-06	8.16e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—ovarian cancer	3.99e-06	8.14e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CB—ovarian cancer	3.99e-06	8.14e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	3.99e-06	8.13e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGFR—ovarian cancer	3.99e-06	8.13e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK1—ovarian cancer	3.97e-06	8.09e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGFR—ovarian cancer	3.97e-06	8.09e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK1—ovarian cancer	3.95e-06	8.06e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGFR—ovarian cancer	3.95e-06	8.06e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK1—ovarian cancer	3.91e-06	7.98e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGFR—ovarian cancer	3.91e-06	7.98e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KRAS—ovarian cancer	3.77e-06	7.68e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KRAS—ovarian cancer	3.75e-06	7.64e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KRAS—ovarian cancer	3.73e-06	7.62e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KRAS—ovarian cancer	3.7e-06	7.54e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTEN—ovarian cancer	3.69e-06	7.53e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CA—ovarian cancer	3.53e-06	7.2e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTEN—ovarian cancer	3.48e-06	7.09e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	3.46e-06	7.06e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTEN—ovarian cancer	3.45e-06	7.03e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CA—ovarian cancer	3.44e-06	7.02e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CA—ovarian cancer	3.43e-06	7e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CA—ovarian cancer	3.4e-06	6.93e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—ovarian cancer	3.35e-06	6.84e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—ovarian cancer	3.35e-06	6.83e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—ovarian cancer	3.33e-06	6.79e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—ovarian cancer	3.32e-06	6.77e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—ovarian cancer	3.29e-06	6.7e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRAS—ovarian cancer	3.2e-06	6.53e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRAS—ovarian cancer	3.18e-06	6.49e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRAS—ovarian cancer	3.17e-06	6.47e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRAS—ovarian cancer	3.14e-06	6.41e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—ovarian cancer	3.06e-06	6.25e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—ovarian cancer	3.05e-06	6.22e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—ovarian cancer	3.04e-06	6.2e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—ovarian cancer	3.01e-06	6.14e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CA—ovarian cancer	2.99e-06	6.09e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—ovarian cancer	2.88e-06	5.88e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—ovarian cancer	2.83e-06	5.76e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—ovarian cancer	2.81e-06	5.73e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—ovarian cancer	2.8e-06	5.72e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—ovarian cancer	2.78e-06	5.66e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.6e-06	5.31e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.45e-06	5e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—ovarian cancer	2.44e-06	4.98e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CA—ovarian cancer	2.43e-06	4.96e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—ovarian cancer	2.13e-06	4.34e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—ovarian cancer	2e-06	4.09e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—ovarian cancer	1.99e-06	4.05e-05	CbGpPWpGaD
